New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
Search
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Digital technology helps patients with complex needs
Digital technology helps patients with complex needs
New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec
The project will use artificial intelligence (A.I.), wearable technologies and electronic health record systems to identify patients who may have type 2 diabetes in Montreal, Quebec
Using AI to transform screening for type 2 diabetes
Using AI to transform screening for type 2 diabetes
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
Using AI to power patient-centric guideline optimization
Using AI to power patient-centric guideline optimization
Information Technology
IT
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
UBC launches Canada's first graduate blockchain training path
UBC launches Canada's first graduate blockchain training path
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients
Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients
Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support
Burlington, ON (October 25, 2023) – In a unique partnership, Boehringer Ingelheim (Canada) Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis
Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada
Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada
Digital Clinical Support Tool Aims to Individualize Guidelines-Based Diabetes Care
BURLINGTON, ON – October 11, 2023 – Boehringer Ingelheim (Canada) Ltd. and BI X, the digital lab of Boehringer Ingelheim, have collaborated to introduce a new digital clinical support tool for Canadian healthcare professionals managing the care
Philanthropic partnership sets sights on sustainable improvements to health care
Philanthropic partnership sets sights on sustainable improvements to health care
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Vaccine protection against different PRRS virus strains
Vaccine protection against different PRRS virus strains
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19